"We are running out of treatment options" for those suffering from antibiotic-resistant infections, Dr. Beverley Isherwood tells the Guardian.
"Without effective antimicrobials and better diagnostics, the success of modern medicine in treating infections, including during general surgery and cancer chemotherapy, amongst others, would be at increased risk."
Isherwood is the program director for Pathways to Antimicrobial Clinical Efficacy at the Medicines Discovery Catapult in the UK, which is investing $30 million in the fight against antimicrobial resistance (AMR) with a goal of bringing new treatments to market by 2023, per a press release.
"Antimicrobial resistance is a truly global challenge that needs a global response," Isherwood says.
"It affects people in every country, and without intervention, it will become an ever-increasing issue."
According to the CDC, an estimated 1.27 million people died in 2019 due to infections caused by bacterial AMR, and that number is expected to rise to 10 million people every year by 2050 and cost the world more than $50 trillion if no action is taken.
"There are not enough current medicines or medicines in development to stay ahead of these resistant infections," Isherwood says.
"The only way to find solutions to this growing challenge is to work
A customized collection of grant news from foundations and the federal government from around the Web.
First Enterprise Business Agency (FEBA), a Nottingham-based business support organization, is a contender for two categories at the first Citi Microentrepreneurship Awards to be held this coming February.